|
WO1994004679A1
(en)
|
1991-06-14 |
1994-03-03 |
Genentech, Inc. |
Method for making humanized antibodies
|
|
CA2158745C
(en)
|
1993-03-25 |
2007-06-19 |
Richard L. Kendall |
Inhibitor of vascular endothelial cell growth factor
|
|
WO1998011244A2
(en)
|
1996-09-11 |
1998-03-19 |
The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services |
Aav4 vector and uses thereof
|
|
KR100816621B1
(ko)
|
1997-04-07 |
2008-03-24 |
제넨테크, 인크. |
항-ｖｅｇｆ 항체
|
|
US6156303A
(en)
|
1997-06-11 |
2000-12-05 |
University Of Washington |
Adeno-associated virus (AAV) isolates and AAV vectors derived therefrom
|
|
US6506559B1
(en)
|
1997-12-23 |
2003-01-14 |
Carnegie Institute Of Washington |
Genetic inhibition by double-stranded RNA
|
|
WO1999061601A2
(en)
|
1998-05-28 |
1999-12-02 |
The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Aav5 vector and uses thereof
|
|
ATE362542T1
(de)
|
1998-11-05 |
2007-06-15 |
Univ Pennsylvania |
Nukleinsäuresequenzen des adeno-assoziierten virus des serotyps i, und vektoren und wirtszellen, die diese enthalten
|
|
AU780231B2
(en)
|
1998-11-10 |
2005-03-10 |
University Of North Carolina At Chapel Hill, The |
Virus vectors and methods of making and administering the same
|
|
DE19956568A1
(de)
|
1999-01-30 |
2000-08-17 |
Roland Kreutzer |
Verfahren und Medikament zur Hemmung der Expression eines vorgegebenen Gens
|
|
US7087411B2
(en)
|
1999-06-08 |
2006-08-08 |
Regeneron Pharmaceuticals, Inc. |
Fusion protein capable of binding VEGF
|
|
JP2003523320A
(ja)
|
1999-09-29 |
2003-08-05 |
ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア |
ウイルスベクターの迅速なｐｅｇ改変方法、高められた遺伝子形質導入のための組成物、高められた物理的安定性を伴う組成物、およびそのための用途
|
|
HK1047109A1
(zh)
|
1999-10-15 |
2003-02-07 |
University Of Massachusetts |
作为指定基因干预工具的rna干预轨迹基因
|
|
ES2336887T5
(es)
|
2000-03-30 |
2019-03-06 |
Whitehead Inst Biomedical Res |
Mediadores de interferencia por ARN específicos de secuencias de ARN
|
|
WO2001089304A1
(en)
|
2000-05-23 |
2001-11-29 |
University Of Rochester |
Method of producing herpes simplex virus amplicons, resulting amplicons, and their use
|
|
WO2001092513A1
(en)
|
2000-05-30 |
2001-12-06 |
Johnson & Johnson Research Pty Limited |
METHODS FOR MEDIATING GENE SUPPRESION BY USING FACTORS THAT ENHANCE RNAi
|
|
CA2456008A1
(en)
|
2000-08-19 |
2002-02-28 |
Axordia Limited |
Stem cell differentiation
|
|
WO2002029858A2
(en)
|
2000-09-29 |
2002-04-11 |
Infineon Technologies North America Corp. |
Deep trench etching method to reduce/eliminate formation of black silicon
|
|
US20030144221A1
(en)
|
2001-07-17 |
2003-07-31 |
Isis Pharmaceuticals Inc. |
Antisense modulation of BCL2-associated X protein expression
|
|
US20070061084A1
(en)
*
|
2002-01-24 |
2007-03-15 |
Ecopia Biosciences, Inc. |
Method, system, and knowledge repository for identifying a secondary metabolite from a microorganism
|
|
US7148342B2
(en)
|
2002-07-24 |
2006-12-12 |
The Trustees Of The University Of Pennyslvania |
Compositions and methods for sirna inhibition of angiogenesis
|
|
US20040023390A1
(en)
|
2002-08-05 |
2004-02-05 |
Davidson Beverly L. |
SiRNA-mediated gene silencing with viral vectors
|
|
SI1633772T1
(sl)
|
2003-06-19 |
2016-06-30 |
Genzyme Corporation |
AAV virioni z zmanjšano imunoreaktivnostjo in uporaba za ta namen
|
|
US9441244B2
(en)
|
2003-06-30 |
2016-09-13 |
The Regents Of The University Of California |
Mutant adeno-associated virus virions and methods of use thereof
|
|
US20060166363A1
(en)
|
2004-01-27 |
2006-07-27 |
Sergei Zolotukhin |
Modified baculovirus expression system for production of pseudotyped rAAV vector
|
|
US7872118B2
(en)
|
2006-09-08 |
2011-01-18 |
Opko Ophthalmics, Llc |
siRNA and methods of manufacture
|
|
EP3028707A1
(en)
|
2009-05-01 |
2016-06-08 |
Ophthotech Corporation |
Methods for treating or preventing ophthalmological diseases
|
|
EP2561073B1
(en)
|
2010-04-23 |
2016-08-24 |
University of Massachusetts |
Cns targeting aav vectors and methods of use thereof
|
|
CN105755044A
(zh)
*
|
2011-04-22 |
2016-07-13 |
加利福尼亚大学董事会 |
具有变异衣壳的腺相关病毒病毒体及其使用方法
|
|
MX367100B
(es)
|
2012-02-17 |
2019-08-05 |
The Children´S Hospital Of Philadelphia |
Composiciones del vector aav y metodos para su transferencia genetica a celulas, organos y tejidos.
|
|
TWI698240B
(zh)
|
2012-05-15 |
2020-07-11 |
澳大利亞商艾佛蘭屈澳洲私營有限公司 |
使用腺相關病毒(aav)sflt-1治療老年性黃斑部退化(amd)
|
|
ES2926774T3
(es)
|
2013-03-15 |
2022-10-28 |
Univ North Carolina Chapel Hill |
Métodos y composiciones para vectores AAV de doble unión de glicano
|
|
EP3151866B1
(en)
|
2014-06-09 |
2023-03-08 |
Voyager Therapeutics, Inc. |
Chimeric capsids
|
|
US11021519B2
(en)
*
|
2015-03-02 |
2021-06-01 |
Adverum Biotechnologies, Inc. |
Compositions and methods for intravitreal delivery of polynucleotides to retinal cones
|
|
US11364308B2
(en)
*
|
2016-05-13 |
2022-06-21 |
4D Molecular Therapeutics Inc. |
Adeno-associated virus variant capsids and methods of use thereof
|
|
AU2017302013B2
(en)
|
2016-07-29 |
2022-05-26 |
The Regents Of The University Of California |
Adeno-associated virus virions with variant capsid and methods of use thereof
|
|
CA3040179A1
(en)
*
|
2016-10-19 |
2018-04-26 |
Adverum Biotechnologies, Inc. |
Modified aav capsids and uses thereof
|
|
JP2020510424A
(ja)
|
2017-02-28 |
2020-04-09 |
アドヴェラム バイオテクノロジーズ， インコーポレイテッド |
改変ａａｖカプシドおよびその使用
|
|
CN111770999A
(zh)
*
|
2017-11-27 |
2020-10-13 |
4D分子治疗有限公司 |
腺相关病毒变体衣壳和用于抑制血管生成的应用
|
|
HRP20260137T1
(hr)
*
|
2019-09-11 |
2026-03-13 |
Adverum Biotechnologies, Inc. |
Liječenje očnih neovaskularnih bolesti upotrebom aav2 varijanti koje kodiraju aflibercept
|
|
CN114729009A
(zh)
*
|
2019-10-31 |
2022-07-08 |
伯尔尼大学 |
用于眼部基因递送的aav载体变体
|